Results Of 3-Year Eficcacy After I Stent Inject Combined With Cataract Surgery In Glaucoma Patients
Published 2024 - 42nd Congress of the ESCRS
Reference: PO979 | Type: Poster | DOI: 10.82333/zjaw-c729
Authors: Ignacio Pereira-Gonzalez* 1 , Maria Marquez Cortes 1 , Marina Jimenez Alcantara 1 , Cristina Delgado Garcia 1 , Maria del mar Banda Velez 1
1Hospital universitario Juan Ramon Jimenez,Huelva,Spain
Purpose
To evaluate the 3-year efficacy after iStent inject insertion combined with cataract surgery in glaucoma patients, in terms of intraocular pressure (IOP), reduction of drug administration and visual acuity (VA).
Setting
Hospital Juan Ramón Jiménez. Huelva. Spain
Methods
Twenty-seven eyes (16 open angle glaucoma, 10 hypertensive and 1 pigmentary glaucoma) were surgically treated by iStent inject implantation (Glaukos, Corporation, CA) combined with cataract surgery. Treatment efficacy was assessed by analyzing differences in mean IOP values before and up to 3 years after surgery, number of topical ocular medications administered and VA, at visits at 15 days, one and a half months, 3 months, 6 months, 1, 2 and 3 years.
Results
The average IOP values began to be significantly lower from one and a half months after surgery and were maintained until 3 years (p<0.01), with a maximum reduction of 24.8% at 6 months. The percentage reduction in the number of drugs was 64.1%, going from an average value of 1.44 drugs before surgery to 0.52 at 3 years (p<0.01). At 59.3% of the eyes were administered 2 or more hypotensive drugs before surgery while at 3 years the percentage was 11.1%. The percentage of eyes not treated with hypotensive drugs increased from 22.2% before surgery to 70.4% 3 years after surgery. The mean VA increases significantly from 0.33 to 0.84 decimal (p<0.01).
Conclusions
The insertion of iStent inject implants combined with cataract surgery is an effective option that is maintained for at least 3 years after surgery.